StockMarketWire.com - Vectura Group said it would receive a $2.5m milestone payment under an exclusive licence agreement with Novartis.

The payment was triggered following the acceptance of Novartis' marketing authorisation application for the approval in Europe of QVM149.

The potential treatment was a potential new inhaled combination therapy for inadequately controlled asthma.


At 8:04am: [LON:VEC] Vectura Group PLC share price was +0.93p at 79.43p



Story provided by StockMarketWire.com